182 related articles for article (PubMed ID: 19390879)
1. A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes.
Pavlaki M; Debeli K; Triantaphyllidou IE; Klouras N; Giannopoulou E; Aletras AJ
J Biol Inorg Chem; 2009 Aug; 14(6):947-57. PubMed ID: 19390879
[TBL] [Abstract][Full Text] [Related]
2. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis by anthracyclines and titanocene dichloride.
Maragoudakis ME; Peristeris P; Missirlis E; Aletras A; Andriopoulou P; Haralabopoulos G
Ann N Y Acad Sci; 1994 Sep; 732():280-93. PubMed ID: 7526759
[TBL] [Abstract][Full Text] [Related]
4. Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice.
Friedrich M; Villena-Heinsen C; Farnhammer C; Schmidt W
Eur J Gynaecol Oncol; 1998; 19(4):333-7. PubMed ID: 9744720
[TBL] [Abstract][Full Text] [Related]
5. A controlled release system of titanocene dichloride by electrospun fiber and its antitumor activity in vitro.
Chen P; Wu QS; Ding YP; Chu M; Huang ZM; Hu W
Eur J Pharm Biopharm; 2010 Nov; 76(3):413-20. PubMed ID: 20854905
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
7. Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride.
Guo M; Guo Z; Sadler PJ
J Biol Inorg Chem; 2001 Sep; 6(7):698-707. PubMed ID: 11681703
[TBL] [Abstract][Full Text] [Related]
8. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the cytotoxicity of titanocene dichloride by aging in organic co-solvent.
Ravera M; Cassino C; Monti E; Gariboldi M; Osella D
J Inorg Biochem; 2005 Dec; 99(12):2264-9. PubMed ID: 16209887
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activity and mode of action of titanocene C.
Olszewski U; Claffey J; Hogan M; Tacke M; Zeillinger R; Bednarski PJ; Hamilton G
Invest New Drugs; 2011 Aug; 29(4):607-14. PubMed ID: 20162321
[TBL] [Abstract][Full Text] [Related]
11. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice.
Kolberg HC; Villena-Heinsen C; Deml MM; Kraemer S; Diedrich K; Friedrich M
Eur J Gynaecol Oncol; 2005; 26(4):398-402. PubMed ID: 16122187
[TBL] [Abstract][Full Text] [Related]
12. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
13. Human tumour xenografts in nude mice: chemotherapy trials with titanocene dichloride in different dosages.
Villena-Heinsen C; Friedrich M; Ertan AK; Schmidt W
Clin Exp Obstet Gynecol; 1998; 25(1-2):5-8. PubMed ID: 9743868
[TBL] [Abstract][Full Text] [Related]
14. Antitumour metallocenes: structure-activity studies and interactions with biomolecules.
Harding MM; Mokdsi G
Curr Med Chem; 2000 Dec; 7(12):1289-303. PubMed ID: 11032972
[TBL] [Abstract][Full Text] [Related]
15. The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model.
Ramos G; Loperena Y; Ortiz G; Reyes F; Szeto A; Vera J; Velez J; Morales J; Morrero D; Castillo L; Dharmawardhane S; Melendez E; Washington AV
Anticancer Res; 2014 Apr; 34(4):1609-15. PubMed ID: 24692689
[TBL] [Abstract][Full Text] [Related]
16. Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride.
Guo M; Sun H; McArdle HJ; Gambling L; Sadler PJ
Biochemistry; 2000 Aug; 39(33):10023-33. PubMed ID: 10955990
[TBL] [Abstract][Full Text] [Related]
17. The effect of a Titanocene Dichloride derivative, Ti IV (C5H5)(2) NCS(2), on the haematopoietic response of Ehrlich tumour-bearing mice.
Valadares MC; Queiroz ML
Eur J Pharmacol; 2002 Mar; 439(1-3):35-42. PubMed ID: 11937090
[TBL] [Abstract][Full Text] [Related]
18. Binding and hydrolysis studies of antitumoural titanocene dichloride and Titanocene Y with phosphate diesters.
Erxleben A; Claffey J; Tacke M
J Inorg Biochem; 2010 Apr; 104(4):390-6. PubMed ID: 20036426
[TBL] [Abstract][Full Text] [Related]
19. Suppression of angiogenesis by the antitumor agent titanocene dichloride.
Bastaki M; Missirlis E; Klouras N; Karakiulakis G; Maragoudakis ME
Eur J Pharmacol; 1994 Jan; 251(2-3):263-9. PubMed ID: 7512041
[TBL] [Abstract][Full Text] [Related]
20. A (1)H NMR study of the interaction of antitumor metallocenes with glutathione.
Mokdsi G; Harding MM
J Inorg Biochem; 2001 Sep; 86(2-3):611-6. PubMed ID: 11566334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
